FUNGIZONE
LOE ApproachingNDAORALSUSPENSION
Approved
Jun 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FUNGIZONE is an oral antifungal suspension approved in 1971 by Bristol Myers Squibb. The product treats systemic fungal infections through an unknown mechanism of action. It represents a legacy small-molecule antifungal therapy with a long clinical history.
LOE Approaching
As LOE approaches, commercial teams are likely focused on transition planning and managing competitive pressure in a contracting market.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
FUNGIZONE offers limited career growth opportunities given its LOE-approaching lifecycle stage and minimal linked job openings. Roles available are primarily focused on protecting remaining market share and managing competitive erosion rather than building or launching new business.
Brand ManagerMedical Science Liaison
Worked on FUNGIZONE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.